KR20170080522A - 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 - Google Patents

글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 Download PDF

Info

Publication number
KR20170080522A
KR20170080522A KR1020160183500A KR20160183500A KR20170080522A KR 20170080522 A KR20170080522 A KR 20170080522A KR 1020160183500 A KR1020160183500 A KR 1020160183500A KR 20160183500 A KR20160183500 A KR 20160183500A KR 20170080522 A KR20170080522 A KR 20170080522A
Authority
KR
South Korea
Prior art keywords
cysteine
ser
glutamine
gln
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020160183500A
Other languages
English (en)
Korean (ko)
Inventor
오의림
이종석
박영진
임창기
정성엽
권세창
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Publication of KR20170080522A publication Critical patent/KR20170080522A/ko
Priority to KR1020190061853A priority Critical patent/KR102401869B1/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020160183500A 2015-12-31 2016-12-30 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 Ceased KR20170080522A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020190061853A KR102401869B1 (ko) 2015-12-31 2019-05-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020150191082 2015-12-31
KR20150191082 2015-12-31
KR1020160163737 2016-12-02
KR20160163737 2016-12-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020190061853A Division KR102401869B1 (ko) 2015-12-31 2019-05-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
KR1020190106691A Division KR102179392B1 (ko) 2015-12-31 2019-08-29 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체

Publications (1)

Publication Number Publication Date
KR20170080522A true KR20170080522A (ko) 2017-07-10

Family

ID=59225193

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020160183500A Ceased KR20170080522A (ko) 2015-12-31 2016-12-30 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
KR1020160183499A Ceased KR20170080521A (ko) 2015-12-31 2016-12-30 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020190061853A Active KR102401869B1 (ko) 2015-12-31 2019-05-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
KR1020190061852A Active KR102367997B1 (ko) 2015-12-31 2019-05-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020190106690A Active KR102179391B1 (ko) 2015-12-31 2019-08-29 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020190106691A Active KR102179392B1 (ko) 2015-12-31 2019-08-29 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
KR1020200093189A Active KR102285377B1 (ko) 2015-12-31 2020-07-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020200093190A Active KR102285378B1 (ko) 2015-12-31 2020-07-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020160183499A Ceased KR20170080521A (ko) 2015-12-31 2016-12-30 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020190061853A Active KR102401869B1 (ko) 2015-12-31 2019-05-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
KR1020190061852A Active KR102367997B1 (ko) 2015-12-31 2019-05-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020190106690A Active KR102179391B1 (ko) 2015-12-31 2019-08-29 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020190106691A Active KR102179392B1 (ko) 2015-12-31 2019-08-29 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
KR1020200093189A Active KR102285377B1 (ko) 2015-12-31 2020-07-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR1020200093190A Active KR102285378B1 (ko) 2015-12-31 2020-07-27 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체

Country Status (32)

Country Link
US (6) US10370426B2 (https=)
EP (3) EP3398961B1 (https=)
JP (5) JP6712323B2 (https=)
KR (8) KR20170080522A (https=)
CN (6) CN109071624B (https=)
AU (4) AU2016382394B2 (https=)
BR (1) BR112018013530A2 (https=)
CA (2) CA3010182A1 (https=)
CL (6) CL2018001776A1 (https=)
CO (2) CO2018006986A2 (https=)
CR (2) CR20180380A (https=)
DK (1) DK3398961T3 (https=)
DO (2) DOP2018000157A (https=)
EA (2) EA038524B1 (https=)
EC (2) ECSP18053055A (https=)
ES (1) ES2925098T3 (https=)
HK (1) HK1258177A1 (https=)
HR (1) HRP20220995T1 (https=)
HU (1) HUE059737T2 (https=)
IL (2) IL260318B2 (https=)
MX (2) MX2018008027A (https=)
PE (2) PE20250556A1 (https=)
PH (2) PH12018501409B1 (https=)
PL (1) PL3398961T3 (https=)
PT (1) PT3398961T (https=)
RS (1) RS63541B1 (https=)
SA (2) SA518391891B1 (https=)
SG (2) SG11201805586SA (https=)
TN (2) TN2018000228A1 (https=)
TW (4) TWI731015B (https=)
WO (2) WO2017116204A1 (https=)
ZA (2) ZA201804997B (https=)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020130749A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
WO2020263063A1 (ko) * 2019-06-28 2020-12-30 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
WO2021145552A1 (ko) * 2020-01-13 2021-07-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 폐질환의 치료 용도
WO2021215801A1 (ko) * 2020-04-20 2021-10-28 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2022015115A1 (ko) * 2020-07-17 2022-01-20 한미약품 주식회사 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도
WO2022035302A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
WO2022035271A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물
WO2022065897A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도
WO2022065898A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
WO2022065899A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
WO2022080989A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
WO2022080991A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도
WO2022080987A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
WO2022164222A3 (ko) * 2021-01-29 2022-09-15 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물
WO2023277620A1 (ko) * 2021-06-30 2023-01-05 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023121371A1 (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
EA201890058A1 (ru) 2015-06-30 2018-07-31 Ханми Фарм. Ко., Лтд. Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR102005457B1 (ko) 2016-06-29 2019-07-30 한미약품 주식회사 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
JP2020506932A (ja) 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
CN110545852B (zh) 2017-02-07 2023-05-26 韩美药品株式会社 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
TWI912614B (zh) 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
EP3939990A4 (en) * 2019-02-15 2023-05-24 Hanmi Fine Chemical Co., Ltd. NOVEL INTERMEDIATE FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND PROCESS FOR THE PRODUCTION THEREOF
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
MX2022002115A (es) 2019-08-19 2022-03-17 Lilly Co Eli Metodos para preparar analogos de incretina.
WO2021066600A1 (ko) * 2019-10-04 2021-04-08 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
TWI795698B (zh) 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN111040022B (zh) * 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN119841865A (zh) 2020-02-07 2025-04-18 加舒布鲁姆生物公司 杂环glp-1激动剂
FI4143183T3 (fi) 2020-04-29 2026-01-07 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
MX2022014670A (es) * 2020-05-22 2023-02-13 Hanmi Pharm Ind Co Ltd Formulacion liquida.
BR112022023609A2 (pt) * 2020-05-22 2023-02-07 Hanmi Pharm Ind Co Ltd Formulação líquida de conjugado de ação prolongada de agonista trigonal de glucagon, glp-1 e gip
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022080985A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
WO2022080984A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 Gip 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
EP4236991A1 (en) 2020-10-30 2023-09-06 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
EP4257597A4 (en) * 2020-12-02 2025-04-02 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
US20230382974A1 (en) * 2020-12-24 2023-11-30 Hanmi Pharm. Co., Ltd. Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use thereof
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20250129135A1 (en) 2021-05-26 2025-04-24 The United Bio-Technology (Hengqin) Co., Ltd Multi-Agonist and Use Thereof
TW202313667A (zh) * 2021-07-30 2023-04-01 大陸商南京明德新藥研發有限公司 含內醯胺橋的多肽化合物
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2023276018A1 (en) * 2022-05-27 2024-11-21 D&D Pharmatech Inc. Peptide compositions and methods of use threof
IL321555B1 (en) 2022-12-23 2026-01-01 Hanmi Pharmaceutical Co Ltd A novel triple agonist for glp-1/gip/glucagon and a pharmaceutical preparation containing it for the prevention or treatment of obesity
PE20252287A1 (es) 2023-01-31 2025-09-18 Lilly Co Eli Agonistas del trirreceptor gip/glp1/gcg y usos de estos
EP4724471A1 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025259064A1 (ko) * 2024-06-13 2025-12-18 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물
WO2025259063A1 (ko) * 2024-06-13 2025-12-18 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 당뇨 예방 또는 치료용 약학적 조성물
WO2025259060A1 (ko) * 2024-06-13 2025-12-18 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물
WO2025259062A1 (ko) * 2024-06-13 2025-12-18 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 신장 질환의 예방 또는 치료용 약학적 조성물
CN120189527B (zh) * 2025-05-27 2026-04-03 广州富肽生物有限公司 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184641A1 (en) * 2003-09-19 2010-07-22 Novo Nordisk A/S Novel Plasma Protein Affinity Tags
US20130203659A1 (en) * 2006-04-20 2013-08-08 Leslie P. Miranda Glp-1 compounds
KR20150096398A (ko) * 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 작용제로서의 엑센딘-4 유도체

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5476304A (en) 1977-11-29 1979-06-18 Tokyo Printing Ink Mfg Co Ltd Ink
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DK1143989T3 (da) * 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
EP1605897B1 (en) * 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TWI423821B (zh) 2007-06-19 2014-01-21 Glucose-containing glucagon-like peptide-1 peptide
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112012018104A2 (pt) 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
EP2528618A4 (en) * 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Ｆｃ受容体およびその製造方法
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
US8507428B2 (en) * 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR20240110072A (ko) 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
BR112013032717A2 (pt) * 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
RS56173B1 (sr) * 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
HRP20180936T1 (hr) * 2012-06-21 2018-12-14 Indiana University Research And Technology Corporation Analozi glukagona koji pokazuju aktivnost prema receptoru za gip
TW201402611A (zh) * 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
PE20151421A1 (es) 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
CN104918961A (zh) 2012-11-20 2015-09-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
CN105324125A (zh) * 2013-03-15 2016-02-10 印第安纳大学研究及科技有限公司 具有长效的前体药物
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
HK1226084A1 (zh) 2013-08-16 2017-09-22 Medimmune Limited 用於治疗糖尿病的gip和glp-1受体双重激动剂
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
ES2822994T3 (es) * 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
EA201890058A1 (ru) 2015-06-30 2018-07-31 Ханми Фарм. Ко., Лтд. Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
TW201718629A (zh) 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
KR20170065016A (ko) 2015-12-02 2017-06-12 한미약품 주식회사 지방산 유도체를 이용한 단백질 결합체 및 이의 제조방법
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184641A1 (en) * 2003-09-19 2010-07-22 Novo Nordisk A/S Novel Plasma Protein Affinity Tags
US20130203659A1 (en) * 2006-04-20 2013-08-08 Leslie P. Miranda Glp-1 compounds
KR20150096398A (ko) * 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 작용제로서의 엑센딘-4 유도체
KR20150096433A (ko) * 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020130749A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
WO2020263063A1 (ko) * 2019-06-28 2020-12-30 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
KR20210002055A (ko) * 2019-06-28 2021-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
KR20210002067A (ko) * 2019-06-28 2021-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
KR20220146369A (ko) * 2019-06-28 2022-11-01 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
WO2021145552A1 (ko) * 2020-01-13 2021-07-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 폐질환의 치료 용도
WO2021215801A1 (ko) * 2020-04-20 2021-10-28 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2022015115A1 (ko) * 2020-07-17 2022-01-20 한미약품 주식회사 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도
WO2022035271A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물
WO2022035302A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
WO2022065897A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도
WO2022065898A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
WO2022065899A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
WO2022080989A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
WO2022080991A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도
WO2022080987A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
WO2022164222A3 (ko) * 2021-01-29 2022-09-15 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물
WO2023277620A1 (ko) * 2021-06-30 2023-01-05 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023121371A1 (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도

Also Published As

Publication number Publication date
ECSP18053055A (es) 2018-07-31
AU2019203891A1 (en) 2019-06-20
IL260310B1 (en) 2023-10-01
JP6712322B2 (ja) 2020-06-17
KR102285377B1 (ko) 2021-08-04
CN116063454A (zh) 2023-05-05
DOP2018000157A (es) 2018-10-15
US20220213164A1 (en) 2022-07-07
CN116059389A (zh) 2023-05-05
US20180311315A1 (en) 2018-11-01
CL2020002034A1 (es) 2020-10-09
IL260318B2 (en) 2024-02-01
HK1258177A1 (en) 2019-11-08
IL260310B2 (en) 2024-02-01
TW202216748A (zh) 2022-05-01
PE20181494A1 (es) 2018-09-18
TW201737945A (zh) 2017-11-01
US20190002520A1 (en) 2019-01-03
DK3398961T3 (da) 2022-08-22
TWI877582B (zh) 2025-03-21
EP3398962A1 (en) 2018-11-07
IL260310A (en) 2018-08-30
PH12018501409B1 (en) 2023-03-10
IL260318A (en) 2018-08-30
TW202330585A (zh) 2023-08-01
PE20250556A1 (es) 2025-02-24
DOP2018000159A (es) 2018-09-30
HK1255834A1 (en) 2019-08-30
TWI807580B (zh) 2023-07-01
PH12018501409A1 (en) 2019-04-08
US10400020B2 (en) 2019-09-03
AU2016382393B2 (en) 2019-07-04
KR20190062344A (ko) 2019-06-05
CR20180381A (es) 2019-01-14
KR102285378B1 (ko) 2021-08-04
CN108699125A (zh) 2018-10-23
JP2019504057A (ja) 2019-02-14
KR20170080521A (ko) 2017-07-10
AU2016382393A1 (en) 2018-08-02
PT3398961T (pt) 2022-09-05
AU2016382394A1 (en) 2018-08-02
CO2018006986A2 (es) 2018-07-10
NZ744321A (en) 2024-04-26
NZ744306A (en) 2024-05-31
HRP20220995T1 (hr) 2022-11-11
CL2020002033A1 (es) 2020-10-09
ZA201804998B (en) 2019-05-29
CN108699125B (zh) 2022-10-28
JP6712323B2 (ja) 2020-06-17
CN116063453A (zh) 2023-05-05
US11332508B2 (en) 2022-05-17
WO2017116204A1 (ko) 2017-07-06
CR20180380A (es) 2018-12-07
EP3985017A1 (en) 2022-04-20
WO2017116205A1 (ko) 2017-07-06
TN2018000228A1 (en) 2019-10-04
CN109071624A (zh) 2018-12-21
CL2022000558A1 (es) 2022-09-23
CO2018006982A2 (es) 2018-07-10
EA038544B1 (ru) 2021-09-13
ECSP18053053A (es) 2018-07-31
PH12018501411B1 (en) 2024-02-23
IL260318B1 (en) 2023-10-01
MX2018008027A (es) 2018-11-29
CA3010182A1 (en) 2017-07-06
RS63541B1 (sr) 2022-09-30
KR102179391B1 (ko) 2020-11-16
JP2022130723A (ja) 2022-09-06
ES2925098T3 (es) 2022-10-13
KR102179392B1 (ko) 2020-11-16
US20190153060A1 (en) 2019-05-23
JP7526039B2 (ja) 2024-07-31
PH12018501411A1 (en) 2019-04-08
CN115920077A (zh) 2023-04-07
KR102367997B1 (ko) 2022-03-02
KR20190060749A (ko) 2019-06-03
CA3010265C (en) 2025-05-20
EP3398961B1 (en) 2022-06-29
JP2019504055A (ja) 2019-02-14
TWI800478B (zh) 2023-05-01
AU2019203891B2 (en) 2021-05-13
BR112018013530A2 (pt) 2018-12-04
KR20190105542A (ko) 2019-09-17
ZA201804997B (en) 2019-05-29
TWI731015B (zh) 2021-06-21
AU2016382394B2 (en) 2019-07-04
MX2018008128A (es) 2018-12-06
BR112018013525A2 (pt) 2018-12-04
KR102401869B1 (ko) 2022-05-25
US20210188937A1 (en) 2021-06-24
PL3398961T3 (pl) 2022-09-26
EP3398961A4 (en) 2019-06-12
KR20200095436A (ko) 2020-08-10
AU2019203888A1 (en) 2019-06-20
CL2018001795A1 (es) 2018-08-10
JP7030894B2 (ja) 2022-03-07
SG11201805586SA (en) 2018-07-30
SA518391903B1 (ar) 2022-08-01
SG11201805573RA (en) 2018-07-30
EA201891359A1 (ru) 2019-01-31
EA038524B1 (ru) 2021-09-09
US20190218269A1 (en) 2019-07-18
CA3010265A1 (en) 2017-07-06
CN109071624B (zh) 2023-01-17
CN115920077B (zh) 2025-07-04
CL2022000557A1 (es) 2022-09-23
TN2018000231A1 (en) 2019-10-04
SA518391891B1 (ar) 2021-07-12
EP3398961A1 (en) 2018-11-07
CL2018001776A1 (es) 2018-08-10
EP3398962A4 (en) 2019-08-07
KR20190104958A (ko) 2019-09-11
AU2019203888B2 (en) 2021-05-13
HUE059737T2 (hu) 2022-12-28
KR20200096184A (ko) 2020-08-11
EA201891360A1 (ru) 2018-12-28
JP2020128428A (ja) 2020-08-27
JP2020171287A (ja) 2020-10-22
US10981967B2 (en) 2021-04-20
TW201730207A (zh) 2017-09-01
US10370426B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
KR102285378B1 (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
JP7399212B2 (ja) グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
KR102395855B1 (ko) 신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물
JP6345216B2 (ja) オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
JP7684902B2 (ja) グルカゴン及びこれを含む組合せ物の治療学的用途
KR20210129614A (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
BR112018013525B1 (pt) Conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20161230

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180314

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20161230

Comment text: Patent Application

PA0302 Request for accelerated examination

Patent event date: 20180314

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

Patent event date: 20161230

Patent event code: PA03021R01I

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180711

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180711

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190125

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181112

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190327

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20190527

Patent event code: PA01071R01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190729

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190527

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190327

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190227

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190125

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181112

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180711

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20190829

Patent event code: PA01071R01D